---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-067556"
form_type: "8-K"
ticker: "REPL"
cik: "0001737953"
company_name: "Replimune Group, Inc."
filed_at: "2024-06-03T23:59:59+00:00"
generated_at: "2026-06-01T06:52:18.370051+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Replimune presents positive RP1/RP2 data at ASCO: 32.7% ORR in melanoma, BLA on track for 2H 2024

## Summary
- RP1+nivolumab in anti-PD-1 failed melanoma (n=156) showed 32.7% ORR by investigator; median duration of response >36 months.
- In primary resistant patients (n=94) ORR 34%; in anti-PD-1+anti-CTLA-4 progressors (n=66) ORR 27.3%.
- RP2 in uveal melanoma (n=17) showed 29.4% ORR and 58.8% DCR as monotherapy or with nivolumab; registration-directed trial planned.
- Company expects central review results Q2 2024; BLA submission for RP1 in 2H 2024; Phase 3 IGNYTE-3 to start before BLA.

## SEC filing metadata
- accession: 0001104659-24-067556
- form_type: 8-K
- ticker: REPL
- cik: 0001737953
- company_name: Replimune Group, Inc.
- filed_at: 2024-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737953/000110465924067556/0001104659-24-067556-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737953/000110465924067556/tm2416257d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-067556
- JSON: https://secwatch.observer/filing/0001104659-24-067556.json
- Plain text: https://secwatch.observer/filing/0001104659-24-067556.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.